Abstract: A system and method are provided for analyzing and reacting to interactions between entities using electronic communication channels. The method includes receiving, via the communications module, data captured from a conversational exchange between a first entity communicating with a second entity using an electronic communication channel. The method also includes analyzing the captured data to detect an indication that the first entity is or was distracted during the conversational exchange, is or was disinterested in a portion of the conversational exchange or missed the portion of the conversational exchange. The method also includes determining based on the indication an action to address the distraction during, disinterest in, or missing of, the portion of the conversational exchange; and providing, via the communications module, an automated message to at least one of the first entity and the second entity for executing the action.

Abstract: The present disclosure generally relates to methods and user interfaces for managing watch face user interfaces. In some embodiments, methods and user interfaces for managing watch faces based on depth data of a previously captured media item are described. In some embodiments, methods and user interfaces for managing clock faces based on geographic data are described. In some embodiments, methods and user interfaces for managing clock faces based on state information of a computer system are described. In some embodiments, methods and user interfaces related to the management of time are described. In some embodiments, methods and user interfaces for editing user interfaces based on depth data of a previously captured media item are described.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: Provided herein are methods for producing an adeno-associated virus (AAV) particle containing an oversized recombinant AAV genome (e.g., greater than 4.7 kb). In some aspects, the invention provides AAV particles and AAV vectors comprising oversized rAAV genomes. Producer cell lines to produce AAV particles comprising oversized genomes are also provided.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: Provided herein are methods for producing an adeno-associated virus (AAV) particle containing an oversized recombinant AAV genome (e.g., greater than 4.7 kb). In some aspects, the invention provides AAV particles and AAV vectors comprising oversized rAAV genomes. Producer cell lines to produce AAV particles comprising oversized genomes are also provided.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: An accelerometer is supported on a print head assembly to determine actual acceleration, and a computer system is used to obtain and store information about error in movement along a specified axis. The method used is to activate a motor for a selected axis at a particular location, then calculate an expected acceleration. The next step is to measure the actual acceleration data and then compute error data. Following that is a step to store error data in the memory as a function of position and error. These steps are repeated for N locations along each specified axis. Then, this error data is referred to during actual printing operations to reduce error.

Abstract: A 3D printer has a casing, a nozzle for printing, an extruder, a heating element, and a print bed. The casing encloses a region above and around the print bed to form a printing zone. The apparatus has a plurality of micro motors for controlling movement of the nozzle during printing. Further, the 3D printer has safer components as compared with the prior art, ideal for use in home and education situations, and includes a rounded edge design of the printer, an improved small and enclosed area of the printer heating element, and a lower power system, reducing the risk of electrical shock.

Abstract: A printbed for 3D printers and 3D printed objects has a hole size and thickness that facilitates release of the printed object, that is sufficiently strong to provide a stable base, and that does not cause warping of the printed object either during printing or during release of the object from the printbed.

Abstract: A 3D printer has a casing, a nozzle for printing, an extruder, a heating element, and a print bed. The casing encloses a region above and around the print bed to form a printing zone. Further, the 3D printer has features adapted for low-noise operation, and is already suitably quiet enough for use in a low-noise environment because it does not generate loud sounds. Specifically, in a quiet office with 37-38 dB of noise, noise emissions were measured while the present invention constructed a 3D printed model, and at six inches from the extruder on the 3D printer, the noise emissions measured 39-58 dB, at three feet away measured 38-43 dB, and at six feet away measured around 37-40 dB.

Abstract: A nozzle and cover for use in 3D printing, including a nozzle body having a relatively flattened end; a nozzle tip protruding a small distance from the flattened end; a disk of material surrounding the nozzle tip, the disk being in contact with the flattened end; and wherein the disk of material prevents sticking of plastic and thereby prevents charring. The device further includes providing the disk of material being composed of PTFE or silicone.

Abstract: Systems and methods for designing and implementing dynamic and template-based web page content are described herein. One example includes a presentation layer software development kit providing a full-featured graphical user interface for the design of web page components and structures. The presentation layer software development kit may integrate with various design, development, compilation, and testing tools to generate production-ready web page output in a scalable architecture. Using the presentation layer software development kit, modifications to the web page content may be generated, tested, and deployed in a real-time basis, reducing design and implementation times.

Abstract: The invention is directed to novel combinations of muscle-specific enhancers and promoter elements useful for achieving persistent expression in the muscle or myocyctes. The muscle-specific promoter elements are derived from a muscle creatine kinase promoter, a troponin I promoter, a skeletal alpha-actin promoter, or a desmin promoter. The muscle-specific enhancer elements are derived from either troponin I internal regulatory elements, muscle creatine kinase enhancers, or desmin enhancers.